Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1077368 | 0.90 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL26366389 | 0.86 | LPAR1 (0.49) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL1395273 | 0.85 | ALDH1A1 (0.69) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL5461723 | 0.84 | ALDH1A1 (0.67) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL21326401 | 0.82 | ALDH1A1 (0.63) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL26566666 | 0.82 | ALDH1A1 (0.63) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL11961104 | 0.81 | ALDH1A1 (0.53) | ALDH1A1CNR1CNR2 | |
| SCHEMBL9718660 | 0.81 | ALDH1A1 (0.60) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL9718817 | 0.81 | ALDH1A1 (0.60) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL4094364 | 0.81 | ALDH1A1 (0.60) | ALDH1A1CNR1CNR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569256-B2 | Cationic lipids and methods for the delivery of therapeutic agents | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20120202871-A1 | CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS | PROTIVA BIOTHERAPEUTICS, INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120202871-A1 | CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS | PROTIVA BIOTHERAPEUTICS, INC. | 2012-08-09 | — | — | US | disclosed |
| WO-2011000106-A1 | IMPROVED CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202871-A1 | CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS | LDLR, NPC1, CETP | ALDH1A1 4573/4885CNR1 3953/4885CNR2 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.